CFG
REGN icon

Citizens Financial Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Citizens Financial Group’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.73M Sell
4,376
-399
-8% -$272K 0.03% 265
2026
Q1 		$3.69M Buy
4,775
+916
+24% +$701K 0.05% 213
2025
Q4 		$2.98M Buy
3,859
+241
+7% +$164K 0.04% 231
2025
Q3 		$2.03M Buy
3,618
+959
+36% +$542K 0.03% 282
2025
Q2 		$1.4M Buy
2,659
+1,871
+237% +$1.04M 0.02% 300
2025
Q1 		$500K Sell
788
-465
-37% -$320K 0.01% 417
2024
Q4 		$893K Sell
1,253
-10,765
-90% -$9.03M 0.02% 313
2024
Q3 		$12.6M Sell
12,018
-112
-0.9% -$125K 0.25% 81
2024
Q2 		$12.7M Buy
12,130
+127
+1% +$123K 0.28% 73
2024
Q1 		$11.6M Sell
12,003
-278
-2% -$264K 0.39% 51
2023
Q4 		$10.8M Sell
12,281
-25
-0.2% -$20.6K 0.37% 57
2023
Q3 		$10.1M Sell
12,306
-394
-3% -$310K 0.41% 55
2023
Q2 		$9.13M Buy
12,700
+75
+0.6% +$57.8K 0.33% 67
2023
Q1 		$10.4M Sell
12,625
-327
-3% -$247K 0.38% 65
2022
Q4 		$9.34M Sell
12,952
-809
-6% -$597K 0.36% 69
2022
Q3 		$9.48M Sell
13,761
-1
-0% -$629 0.42% 59
2022
Q2 		$8.14M Sell
13,762
-183
-1% -$119K 0.34% 72
2022
Q1 		$9.74M Sell
13,945
-181
-1% -$115K 0.34% 69
2021
Q4 		$8.92M Sell
14,126
-251
-2% -$154K 0.3% 77
2021
Q3 		$8.7M Sell
14,377
-338
-2% -$210K 0.32% 78
2021
Q2 		$8.22M Buy
+14,715
New +$7.45M 0.36% 76
2020
Q3 		– Sell
-63
Closed -$39K – 777
2020
Q2 		$39K Buy
63
+36
+133% +$20.4K ﹤0.01% 512
2020
Q1 		$13K Buy
27
+10
+59% +$4.13K ﹤0.01% 694
2019
Q4 		$6K Buy
+17
New +$5.72K ﹤0.01% 848
2019
Q3 		– Sell
-7
Closed -$2K – 890
2019
Q2 		$2K Sell
7
-65
-90% -$21.6K ﹤0.01% 760
2019
Q1 		$30K Buy
+72
New +$29.6K ﹤0.01% 404
2016
Q1 		– Sell
-2
Closed -$3K – 763
2015
Q4 		$3K Buy
+2
New +$1.08K ﹤0.01% 623

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Citizens Financial Group's REGN Position: Q2 2026 in Review

Citizens Financial Group reduced its Regeneron Pharmaceuticals (REGN) stake by 8.4% in Q2 2026, selling an estimated $272K and leaving 4,376 shares worth $2.73M. The position accounts for 0.03% of the portfolio, ranked #265.

Citizens Financial Group first reported a position in REGN in Q4 2015 and has held it in 27 quarters since. The position peaked at $12.7M in Q2 2024. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Citizens Financial Group held 4,376 shares of Regeneron Pharmaceuticals worth $2.73M as of Q2 2026.
  • Citizens Financial Group sold 399 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $272K.
  • Regeneron Pharmaceuticals made up 0.03% of Citizens Financial Group's portfolio in Q2 2026, its #265 holding.
  • Citizens Financial Group first reported a position in Regeneron Pharmaceuticals in Q4 2015 and has held it in 27 quarters since.
  • Citizens Financial Group's Regeneron Pharmaceuticals position peaked at $12.7M in Q2 2024.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Citizens Financial Group's 13F filing for Q2 2026, filed 7 Aug 2026.